300 TNBC patients have been included in a multicenter, prospective, non-randomized trial aimed to identify predictors of response to TCb in the neoadjuvant setting
(NCT01560663)....In terms of response, significant differences in FOXA1 expression levels were found between responders and non-responders...with responders showing a lower FOXA1 expression level....FOXA1 is overexpressed in TNBC tumors who do not achieve pCR with neoadjuvant TCb chemotherapy, correlating with non-basal tumor subtypes.